Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Therapeutic options in coronary artery disease: focusing on the guidelines Schwartz LCan J Cardiol 2009[Jan]; 25 (1): 19-24There are three options for the treatment of patients with coronary artery disease: coronary artery bypass graft surgery (CABG), percutaneous coronary intervention (PCI) and optimal medical treatment alone. While there has been an active interface between CABG and PCI, medical treatment has not been as vociferously advocated. However, it performs well in randomized trials and is still a treatment arm in studies such as the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. The present review compares these options in acute and chronic coronary syndromes, including the indications for each as summarized by recent American College of Cardiology and American Heart Association guidelines. While the landscape in Canada is changing for CABG and PCI, with an increase in the latter procedure for patients with multivessel disease, optimal medical treatment alone is very effective. There are few subsets, particularly in chronic syndromes, in which revascularization is indicated for prognosis alone.|*Thrombolytic Therapy[MESH]|Acute Coronary Syndrome/drug therapy/*therapy[MESH]|Adrenergic beta-Antagonists/therapeutic use[MESH]|Angioplasty, Balloon, Coronary[MESH]|Anticoagulants/therapeutic use[MESH]|Coronary Artery Bypass[MESH]|Coronary Disease/drug therapy/*therapy[MESH]|Humans[MESH]|Platelet Aggregation Inhibitors/therapeutic use[MESH]|Practice Guidelines as Topic[MESH] |
